+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Drug Class (Entry & Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 75 Pages
  • October 2023
  • Region: Global
  • Grand View Research
  • ID: 5899609
Description Jump to:
The global Human Immunodeficiency Virus (HIV)-1 therapeutics market size is expected to reach USD 11.34 billion by 2030, expanding at a CAGR of 1.5% from 2023 to 2030. HIV continues to be one of the most challenging public health issues worldwide.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc. The estimated number of people suffering from HIV in 2015 was recorded to be more than 35 million according to AVERT, a UK-based HIV and AIDS charity.

HIV has vastly affected people from developing and under developed countries, mainly the Asian and African regions. As this infection is not curable at present, the primary aim of antiretroviral therapy is to suppress viral replication in patients usinganti-retroviral agents that are grouped into six different drug classes based on their mechanism of action.

The combination therapy entails medicines from at least two to three drug classes as each class targets different steps in the HIV lifecycle. The combination of drugs is chosen based on patients’ medical history, predisposition to adverse effects of antiretroviral drugs, co-infections with other diseases, and others.

Human Immunodeficiency Virus Therapeutics Market Report Highlights

  • Integrase inhibitors segment is expected to be the fastest growing class of antiretroviral drugs owing to the expected launch of additional integrase inhibitors by major players such as Gilead Sciences, In. and Merck & Co., Inc.
  • North America held the largest market share in 2022 with a share of over 51.5%. Easier access to diagnostic facilities is one of the key factors supporting sector expansion in this region.
  • Asia Pacific is projected to be the fastest growing regional segment and will retain its position over the forecast period owing to the enhancing healthcare infrastructure and presence of suitable government initiatives favoring growth
  • Gilead Sciences, Inc. was the leader in HIV-1 therapeutics sector with respect to market share and drug portfolio, followed byViiV Healthcare in 2015. In addition, in the coming years other small players are expected to enter this sector with their pipeline drugs.
  • Other important players in this industry include AbbVie, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Boehringer Ingelheim GmbH.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Drug type
1.1.2. Drug class
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Analyst's internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug type outlook
2.2.2. Drug class outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Human Immunodeficiency Virus Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Human Immunodeficiency Virus Therapeutics: Market Analysis Tools
3.4.1. Industry Analysis-Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Human Immunodeficiency Virus Therapeutics Market: Drug Type Estimates & Trend Analysis
4.1. Human Immunodeficiency Virus Therapeutics Market: Key Takeaways
4.2. Human Immunodeficiency Virus Therapeutics Market: Drug Type Movement & Market Share Analysis, 2022 & 2030
4.3. Branded Drugs
4.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Generic Drugs
4.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Human Immunodeficiency Virus Therapeutics Market: Drug Class Estimates & Trend Analysis
5.1. Human Immunodeficiency Virus Therapeutics Market: Key Takeaways
5.2. Human Immunodeficiency Virus Therapeutics Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
5.3. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
5.3.1. Nucleoside-analog reverse transcriptase inhibitors (NRTIs) market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.4.1. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Entry and Fusion Inhibitors
5.5.1. Entry and fusion inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Protease Inhibitors (PIs)
5.6.1. Protease inhibitors (PIs) market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Integrase Inhibitors
5.7.1. Integrase inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Coreceptor Antagonists
5.8.1. Coreceptor antagonists market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Human Immunodeficiency Virus Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Human Immunodeficiency Virus Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. North America market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. U.S. market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Canada market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4. Europe
6.4.1. Europe market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.2. UK
6.4.2.1. UK market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.3. Germany
6.4.3.1. Germany market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.4. France
6.4.4.1. France market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.5. Italy
6.4.5.1. Italy market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.6. Spain
6.4.6.1. Spain market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.7. Sweden
6.4.7.1. Sweden market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.8. Norway
6.4.8.1. Norway market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.9. Denmark
6.4.9.1. Denmark market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Asia Pacific market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.2. Japan
6.5.2.1. Japan market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.3. China
6.5.3.1. China market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.4. India
6.5.4.1. India market estimates and forecasts, 2018-2030 (USD Million) (Revenue, USD Million)
6.5.5. Australia
6.5.5.1. Australia market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.6. Thailand
6.5.6.1. Thailand market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.7. South Korea
6.5.7.1. South Korea market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Latin America market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.6.2. Brazil
6.6.2.1. Brazil market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.6.3. Mexico
6.6.3.1. Mexico market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.6.4. Argentina
6.6.4.1. Argentina market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7. MEA
6.7.1. MEA market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million) (Revenue, USD Million)
6.7.3. South Africa
6.7.3.1. South Africa market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7.4. UAE
6.7.4.1. UAE market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7.5. Kuwait
6.7.5.1. Kuwait market estimates and forecasts, 2018-2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. AbbVie Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Boehringer Ingelheim International GmbH
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Bristol-Myers Squibb Company
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Cipla Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Genentech, Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Gilead Sciences, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Merck & Co., Inc.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. ViiV Healthcare
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 3 North America human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 4 North America human immunodeficiency virus therapeutics market, by region, 2018-2030 (USD Million)
Table 5 U.S. human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 6 U.S. human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 7 Canada human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 8 Canada human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 9 Europe human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 10 Europe human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 11 Europe human immunodeficiency virus therapeutics market, by region, 2018-2030 (USD Million)
Table 12 Germany human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 13 Germany human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 14 UK human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 15 UK human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 16 France human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 17 France human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 18 Italy human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 19 Italy human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 20 Spain human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 21 Spain human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 22 Sweden human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 23 Sweden human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 24 Norway human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 25 Norway human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 26 Denmark human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 27 Denmark human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 28 Asia Pacific human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 29 Asia Pacific human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 30 Asia Pacific human immunodeficiency virus therapeutics market, by region, 2018-2030 (USD Million)
Table 31 China human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 32 China human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 33 Japan human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 34 Japan human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 35 India human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 36 India human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 37 Australia human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 38 Australia human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 39 Thailand human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 40 Thailand human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 41 South Korea human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 42 South Korea human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 43 Latin America human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 44 Latin America human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 45 Latin America human immunodeficiency virus therapeutics market, by region, 2018-2030 (USD Million)
Table 46 Brazil human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 47 Brazil human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 48 Mexico human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 49 Mexico human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 50 Argentina human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 51 Argentina human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 52 Middle East and Africa human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 53 Middle East and Africa human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 54 Middle East and Africa human immunodeficiency virus therapeutics market, by region, 2018-2030 (USD Million)
Table 55 South Africa human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 56 South Africa human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 57 Saudi Arabia human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 58 Saudi Arabia human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 59 UAE human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 60 UAE human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
Table 61 Kuwait human immunodeficiency virus therapeutics market, by drug type, 2018-2030 (USD Million)
Table 62 Kuwait human immunodeficiency virus therapeutics market, by drug class, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Human immunodeficiency virus therapeutics: Market outlook
Fig. 9 Human immunodeficiency virus therapeutics: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Human immunodeficiency virus therapeutics market driver impact
Fig. 15 Human immunodeficiency virus therapeutics market restraint impact
Fig. 16 Human immunodeficiency virus therapeutics market strategic initiatives analysis
Fig. 17 Human immunodeficiency virus therapeutics market: Drug type movement analysis
Fig. 18 Human immunodeficiency virus therapeutics market: Drug type outlook and key takeaways
Fig. 19 Branded drugs market estimates and forecasts, 2018-2030 (USD Million)
Fig. 20 Generic drugs market estimates and forecasts, 2018-2030 (USD Million)
Fig. 21 Human immunodeficiency virus therapeutics market: Drug class movement analysis
Fig. 22 Human immunodeficiency virus therapeutics market: Drug class outlook and key takeaways
Fig. 23 Nucleoside-analog reverse transcriptase inhibitors (NRTIs) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 24 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 25 Entry and fusion inhibitors market estimates and forecasts, 2018-2030 (USD Million)
Fig. 26 Protease inhibitors (PIs) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 27 Integrase inhibitors market estimates and forecasts, 2018-2030 (USD Million)
Fig. 28 Coreceptor antagonists market estimates and forecasts, 2018-2030 (USD Million)
Fig. 29 Global human immunodeficiency virus therapeutics market: Regional movement analysis
Fig. 30 Global human immunodeficiency virus therapeutics market: regional outlook and key takeaways
Fig. 31 North America market estimates and forecasts, 2018-2030 (USD Million)
Fig. 32 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Fig. 33 Canada market estimates and forecasts, 2018-2030 (USD Million)
Fig. 34 Europe market estimates and forecasts, 2018-2030 (USD Million)
Fig. 35 UK market estimates and forecasts, 2018-2030 (USD Million)
Fig. 36 Germany market estimates and forecasts, 2018-2030 (USD Million)
Fig. 37 France market estimates and forecasts, 2018-2030 (USD Million)
Fig. 38 Italy market estimates and forecasts, 2018-2030 (USD Million)
Fig. 39 Spain market estimates and forecasts, 2018-2030 (USD Million)
Fig. 40 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Fig. 41 Norway market estimates and forecasts, 2018-2030 (USD Million)
Fig. 42 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Fig. 43 Asia Pacific market estimates and forecasts, 2018-2030 (USD Million)
Fig. 44 Japan market estimates and forecasts, 2018-2030 (USD Million)
Fig. 45 China market estimates and forecasts, 2018-2030 (USD Million)
Fig. 46 India market estimates and forecasts, 2018-2030 (USD Million)
Fig. 47 Australia market estimates and forecasts, 2018-2030 (USD Million)
Fig. 48 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Fig. 49 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Fig. 50 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Fig. 51 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Fig. 52 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Fig. 53 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Fig. 54 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Fig. 55 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Fig. 56 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Fig. 57 UAE market estimates and forecasts, 2018-2030 (USD Million)
Fig. 58 Kuwait market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • ViiV Healthcare

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages75
PublishedOctober 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 10.33 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.34 Billion
Compound Annual Growth Rate1.5%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

HIV Drugs: Global Strategic Business Report - Product Image

HIV Drugs: Global Strategic Business Report

  • Report
  • 164 Pages
  • Global
From
North America HIV Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

North America HIV Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 124 Pages
  • North America
From
Global Human Immunodeficiency Virus Therapeutics Market by Drug Class (Coreceptor Antagonists, Entry & Fusion Inhibitors, Integrase Inhibitors), End-User (Hospitals & Clinics, Specialty Centers), Distribution Channel - Forecast 2024-2030 - Product Image

Global Human Immunodeficiency Virus Therapeutics Market by Drug Class (Coreceptor Antagonists, Entry & Fusion Inhibitors, Integrase Inhibitors), End-User (Hospitals & Clinics, Specialty Centers), Distribution Channel - Forecast 2024-2030

  • Report
  • 194 Pages
  • Global
From
Human Respiratory Syncytial Virus Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Product Type - Product Image

Human Respiratory Syncytial Virus Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 92 Pages
  • Global
From
HIV integrase inhibitors - Pipeline Insight, 2024 - Product Image

HIV integrase inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.